Literature DB >> 14592696

Characterization of solid-state forms of celecoxib.

Garima Chawla1, Piyush Gupta, R Thilagavathi, Asit K Chakraborti, Arvind K Bansal.   

Abstract

This study deals with the generation and characterization of various solid-state forms of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor. The drug was subjected to polymorphic screen using different solvents to explore the possibility of existence of different solid forms. N,N-Dimethyl acetamide (DMA) and N,N-dimethyl formamide (DMF) yielded solvates in 1:1 stoichiometric ratio. Quench cooling of the melt resulted in amorphous form of the drug. All these solid-state forms were characterized by thermoanalytical (DSC, TGA, HSM), crystallographic (XRD), microscopic (polarized, SEM), spectroscopic (FTIR), and elemental analysis techniques. Solubility and van't Hoff studies were carried out for their thermodynamic interpretation. Influence of morphology of different solid-state forms on flow behavior was also investigated. Molecular modeling studies were used to elucidate the interaction between solute and solvent molecules in the solvate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14592696     DOI: 10.1016/s0928-0987(03)00201-x

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  17 in total

1.  Release profile and characteristics of electrosprayed particles for oral delivery of a practically insoluble drug.

Authors:  Adam Bohr; Jakob Kristensen; Mark Dyas; Mohan Edirisinghe; Eleanor Stride
Journal:  J R Soc Interface       Date:  2012-04-25       Impact factor: 4.118

2.  Design and evaluation of celecoxib porous particles using melt sonocrystallization.

Authors:  Anant Paradkar; Manish Maheshwari; Ravindra Kamble; Ian Grimsey; Peter York
Journal:  Pharm Res       Date:  2006-06-07       Impact factor: 4.200

3.  Critical solvent properties affecting the particle formation process and characteristics of celecoxib-loaded plga microparticles via spray-drying.

Authors:  Feng Wan; Adam Bohr; Morten Jonas Maltesen; Simon Bjerregaard; Camilla Foged; Jukka Rantanen; Mingshi Yang
Journal:  Pharm Res       Date:  2012-12-11       Impact factor: 4.200

4.  Influence of microcrystal formulation on in vivo absorption of celecoxib in rats.

Authors:  Mohamed Nasr
Journal:  AAPS PharmSciTech       Date:  2013-03-30       Impact factor: 3.246

5.  Molecular indicators of surface and bulk instability of hot melt extruded amorphous solid dispersions.

Authors:  Ziyi Yang; Kathrin Nollenberger; Jessica Albers; Duncan Craig; Sheng Qi
Journal:  Pharm Res       Date:  2014-10-01       Impact factor: 4.200

6.  Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug.

Authors:  Michael Morgen; Corey Bloom; Ron Beyerinck; Akintunde Bello; Wei Song; Karen Wilkinson; Rick Steenwyk; Sheri Shamblin
Journal:  Pharm Res       Date:  2011-08-24       Impact factor: 4.200

7.  Agglomeration of Celecoxib by Quasi Emulsion Solvent Diffusion Method: Effect of Stabilizer.

Authors:  Maryam Maghsoodi; Ali Nokhodchi
Journal:  Adv Pharm Bull       Date:  2016-12-22

8.  Design and Evaluation of a Novel Felbinac Transdermal Patch: Combining Ion-Pair and Chemical Enhancer Strategy.

Authors:  Nannan Liu; Wenting Song; Tian Song; Liang Fang
Journal:  AAPS PharmSciTech       Date:  2015-06-13       Impact factor: 3.246

9.  Devitrification of amorphous celecoxib.

Authors:  Piyush Gupta; Arvind K Bansal
Journal:  AAPS PharmSciTech       Date:  2005-09-30       Impact factor: 3.246

10.  Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals.

Authors:  Sharad B Murdande; Michael J Pikal; Ravi M Shanker; Robin H Bogner
Journal:  Pharm Res       Date:  2010-09-22       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.